Acceleron (XLRN) option implied volatility flat into Phase III Believe results

Acceleron Pharma (NASDAQ: XLRN) July call option implied volatility is at 62, August is at 56; compared to its 52-week range of 37 to 152 into announcing with its partner Celgene (CELG) positive Phase III Believe results for luspatercept in transfusion dependent beta thalassemia.

You May Also Be Interested In

• Darden Restaurants (DRI) call put ratio 1.9 calls to 1 put as share price up 2.6% into the expected release of quarter results
• SpaceX (SPCX) call put ratio 1.5 calls to 1.1 puts as share price at $158
• FedEx Freight (FDXF) call put ratio 2.7 calls to 1 put into quarter results